Y Intercept Hong Kong Ltd Buys New Position in Kyverna Therapeutics, Inc. $KYTX

Y Intercept Hong Kong Ltd bought a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 114,841 shares of the company’s stock, valued at approximately $991,000.

Several other hedge funds have also recently modified their holdings of KYTX. Public Employees Retirement System of Ohio bought a new position in Kyverna Therapeutics in the 3rd quarter worth $28,000. Qube Research & Technologies Ltd bought a new stake in Kyverna Therapeutics during the second quarter worth approximately $43,000. Rhumbline Advisers raised its stake in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares during the period. Ameriprise Financial Inc. bought a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth approximately $77,000. Finally, Bank of America Corp DE grew its stake in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Analyst Upgrades and Downgrades

KYTX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. cut their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $30.00.

Kyverna Therapeutics Stock Down 13.6%

Shares of KYTX stock traded down $1.33 during trading on Friday, reaching $8.48. The company’s stock had a trading volume of 1,991,001 shares, compared to its average volume of 1,200,396. Kyverna Therapeutics, Inc. has a 1-year low of $2.80 and a 1-year high of $13.67. The stock’s 50-day moving average price is $8.72 and its 200 day moving average price is $8.65. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The company has a market capitalization of $515.50 million, a price-to-earnings ratio of -2.59 and a beta of 1.87.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. On average, research analysts anticipate that Kyverna Therapeutics, Inc. will post -2.78 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.